Trial Profile

A Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3090106 in Subjects With Sjogren's Syndrome

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Jul 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tibulizumab (Primary)
Indications Sjogren's syndrome
Focus Adverse reactions
Sponsors Eli Lilly and Company

Most Recent Events

15 Jun 2024 Results(n=25) evaluating pharmacokinetic, and pharmacologic activity of tibulizumab , presented at the 25th Annual Congress of the European League Against Rheumatism
14 Jun 2024 According to a Zura Bio media release, data from this trial presented at the Annual European Congress of Rheumatology (EULAR) 2024
14 Jun 2024 Results published in the Zura Bio Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com